Home infection
 

Keywords :   


Tag: infection

Increasing soybean meal in diet may play role in battling infection in weanling pigs

2015-09-17 18:08:00| National Hog Farmer

Source: University of Illinois University of Illinois has found that increasing concentrations of soybean meal (SBM) in the diets of weanling pigs, above industry standards, may be beneficial for pigs that are infected with the porcine reproductive and respiratory syndrome virus (PRRSV). read more

Tags: play role increasing diet

 

Awareness Raised of Mild Infection that Resembles FMD

2015-09-04 02:00:00| ThePigSite - Industry News

CANADA - The executive director of the US based Swine Health Information Centre is advising pork producers to be on the watch for signs of Seneca Valley Virus, writes Bruce Cochrane.

Tags: raised awareness infection mild

 
 

How much will a trich infection cost you? The numbers arent pretty

2015-07-30 16:23:00| Beef

Trich is a silent thiefsilent, that is, until a rancher with a herd chronically infected with trich realizes just how much money could have been pocketed if the herd was clean. Heres a look at the numbers. read more

Tags: the you cost numbers

 

Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection

2015-07-28 12:30:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Company Granted FDA Priority Review with Target Action Date of January 28, 2016 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Language: English Contact: MerckMedia:Doris Li, (908) 246-5701Sarra Herzog, (201) 669-6570orInvestor:Joe Romanelli, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: and food application treatment

 

Merck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Infection

2015-07-23 17:02:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for grazoprevir/elbasvir (100mg/50mg), an investigational, once-daily, single-tablet combination therapy for the treatment of adult patients with chronic hepatitis C (HCV) genotypes (GT) 1, 3, 4 or 6 infection.1 The EMA will initiate review of the MAA under accelerated assessment timelines. Language: English Contact: Merck & Co., Inc.Media:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestor:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of application marketing treatment

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] next »